My Tiny Feed

dw.com

Lecanemab and the fight against Alzheimer's

New research sheds light on the cause of cell death in Alzheimer's disease, potentially opening new avenues for treatment, while the drug Lecanemab offers some hope in slowing progression.

Read original article in Romanian

Romanian

Germany

HealthResearchDementiaTreatmentMedicineAlzheimer's

FdaEmaUniversity College LondonNational Institute On AgingNih

Bart De Strooper

What is Lecanemab and what is its current status?: Lecanemab is a new drug that shows promise in slowing the progression of Alzheimer's disease, although it cannot cure it. It targets amyloid protein, a key factor in the disease's development.
What were the initial and subsequent decisions by the EMA regarding Lecanemab?: The European Medicines Agency (EMA) initially rejected lecanemab due to concerns about serious side effects, but later approved it for patients with a lower risk of such side effects.
What are the potential implications of the new findings for Alzheimer's treatment?: Researchers hope that understanding the link between abnormal proteins, MEG3, and necroptosis will lead to the development of new drugs that can effectively combat Alzheimer's disease by preventing neuronal death.
How many people are affected by dementia globally, and what is the projected increase?: Approximately 55 million people worldwide suffer from dementia, including Alzheimer's disease, and this number is projected to rise dramatically by 2050 due to an aging global population.
What is the newly discovered connection between abnormal proteins and cell death in Alzheimer's?: A new study suggests a direct link between abnormal amyloid and tau proteins, leading to necroptosis (a type of cell death) in Alzheimer's patients. Blocking the molecule MEG3, which is produced in this process, may help prevent neuron death.

Apr 20, 04:10

Measles-Infected Doctor Treats Patients; HHS Secretary's Endorsement Sparks Outrage

During a Texas measles outbreak, Dr. Ben Edwards treated children while visibly ill with measles, raising concerns about potential transmission. Health Secretary Robert F. Kennedy Jr. later praised Edwards, sparking criticism from public health experts who cited the considerable risk to patients and the community.

Apr 20, 01:10

Biophilic Design: Enhancing Brain Function Through Nature-Inspired Environments

Biophilic design, integrating natural elements into buildings, improves cognitive function and reduces stress; studies show it lowers cortisol, boosts mood, and enhances productivity, especially crucial given that people spend over 90% of their time indoors.

Apr 20, 01:10

Mindful Movement: Small Actions, Big Health Impacts

Research shows brief, intentional movements significantly improve physical and mental well-being, offering accessible, high-impact interventions across various populations, unlike traditional fitness.

Apr 20, 01:10

Menopause: From Medical Issue to Empowerment Paradigm

The global perspective on menopause is changing from a medical problem to a period of empowerment and equity, addressing diverse cultural needs and advocating for inclusive workplace accommodations to support menopausal women.